There is growing evidence that MTHFR polymorphism testing has minimal clinical utility and therefore should not be prescribed as part of a routine evaluation for thrombophilia according to the American Congress of Obstetricians and Gynecologists, the American College of Medical Genetics and Genomics, and the British Society for Haematology (166–169). Here, MTHFR is linked to Rare hereditary thrombophilia.